R&D Center-Innovation and service-Tibet WeiXinKang Medicine CO., LTD.

Weixinkang medicine R&D Center


    As the core business of the company, the R&D started in 2002. Based on R&D and innovation, at the beginning of the establishment, the company adheres to the clinical need oriented guideline and insists on the combination of imitation and innovation to constantly develop new products with independent intellectual property rights. After years of capital investment, technical research and knowledge accumulation, the R&D center has initially formed a complete-majored systematic technology development system, and has trained a research team of about 160 people mainly composed of doctorates, masters and undergraduates, with continuous innovation ability for drug research and development. 

    The R&D center has formed three major technology platforms: "new injection technology platform", "large compound preparation technology platform", "new freeze-drying technology platform", and has extended to oral solid preparations; the company has obtained a total of 12 invention patents, 14 new drug certificates and helped business partners obtain 59 drug registration certificates under the technical support of the company. It has obtained obvious advantages in the aspects like intravenous vitamin supplements, intravenous iron supplements and intravenous potassium and magnesium supplements. The company regards market as the guide, technology as the core, talent as the foundation and innovation as the soul, and strives to become an influential, competitive modern R&D enterprise in China.